Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
HS235 · 2 trials · 3 indications
An AE is any untoward medical occurrence in a participant or clinical trial participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. The incidence and number of participants who experience an AE will be reported.
| Arm | Type | Description |
|---|---|---|
| Investigational Product | EXPERIMENTAL | HS235 Subcutaneous Injection |
| Placebo | PLACEBO_COMPARATOR | Subcutaneous Injection |
| HS235 | EXPERIMENTAL | HS235 Subcutaneous Injection |
| Name | Type | Description |
|---|---|---|
| HS235 | BIOLOGICAL | Subcutaneous Injection |
| Placebo | OTHER | Subcutaneous Injection |
Inclusion Criteria: Participants are eligible to be included in the study only if they meet at least all the following criteria: 1. Male or female, ≥ 18 years of age. 2. \[Sub-population A only - using a remote PAP sensor\]- Ambulatory PAP monitoring (e.g., CardioMEMS™ HF System or Cordella™ HF Sy...
Top 13 of 15 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 8 | PHASE3 | Sotatercept, Riociguat, Frespaciguat |
| United Therapeutics Corporation | UTHR | 5 | PHASE3 | Ralinepag, Tyvaso (treprostinil) |
| Insmed Incorporated | INSM | 4 | PHASE3 | Treprostinil Palmitil |
| Johnson & Johnson | JNJ | 4 | PHASE3 | selexipag, Macitentan |
| Liquidia Corporation | LQDA | 4 | PHASE3 | L606, LIQ861 Treprostinil, LIQ861 |
| Tenax Therapeutics, Inc. | TENX | 3 | PHASE3 | Levosimendan (TNX-103) |
| Inhibikase Therapeutics, Inc. | IKT | 2 | PHASE3 | IKT-001 |
| Roivant Sciences Ltd. | ROIV | 3 | PHASE3 | Mosliciguat |
| Regeneron Pharmaceuticals, Inc. | REGN | 1 | PHASE2 | REGN13335 |
| Tectonic Therapeutic Inc | TECX | 2 | PHASE2 | TX45 |
| Gossamer Bio, Inc. | GOSS | 1 | PHASE3 | Seralutinib |
| Pfizer Inc. | PFE | 1 | PHASE2 | PF-07868489 |
| GSK plc Sponsored ADR | GSK | 2 | PHASE1 | HS235 |
HS235 is an investigational monoclonal antibody being developed by GSK plc for pulmonary arterial hypertension and pulmonary hypertension. It is in Phase 1 clinical development and has not been approved by the FDA. GSK trades on the New York Stock Exchange under the ticker GSK.
HS235 is being studied for the treatment of pulmonary arterial hypertension in adults, and also for pulmonary hypertension in obese patients with heart failure with preserved ejection fraction. It is investigational and has not been approved for any indication. Both programs are in Phase 1.
HS235 is developed by GSK plc, which trades under the ticker GSK. GSK is running the Phase 1 clinical program for the antibody across pulmonary arterial hypertension and pulmonary hypertension indications, including sites in the United States and Spain.
HS235 is in Phase 1 clinical development. It is investigational and has not received FDA approval. The program includes two recruiting Phase 1 trials, one in adults with pulmonary arterial hypertension and one in obese participants with pulmonary hypertension and heart failure with preserved ejection fraction.
HS235 is being evaluated in two recruiting Phase 1 trials. NCT07143448 is a placebo-controlled study of HS235 in adults with pulmonary arterial hypertension, enrolling 90 participants in the United States and Spain. NCT07123779 studies HS235 in obese participants with pulmonary hypertension and heart failure with preserved ejection fraction, enrolling 126 participants in the United States.
Yes. The HS235 Phase 1 program uses randomized, double-blind, placebo-controlled designs. NCT07143448 is a randomized, double-blind, placebo-controlled study of HS235 in adults with pulmonary arterial hypertension, and NCT07123779 is a randomized, double-blind, placebo-controlled study in obese participants with pulmonary hypertension and heart failure with preserved ejection fraction.